Feature

MDMA therapy for loneliness? Researchers say it could work


 

Some call the drug “ecstasy” or “molly.” Researchers are calling it a potential tool to help treat loneliness.

As public health experts sound the alarm on a rising loneliness epidemic in the United States and across the globe, early research is finding that MDMA could increase social connectedness and reduce defensiveness in some people — effects that some say could, in combination with therapy, help combat loneliness.

In the latest study, MDMA “led to a robust increase in feelings of connection” among people socializing in a controlled setting. Participants were dosed with either MDMA or a placebo and asked to chat with a stranger. Afterward, those who took MDMA said their companion was more responsive and attentive, and that they had plenty in common. The drug also “increased participants’ ratings of liking their partners, feeling connected and finding the conversation enjoyable and meaningful.”

The study was small — just 18 participants — but its results “have implications for MDMA-assisted therapy,” the authors wrote. “This feeling of connectedness could help patients feel safe and trusting, thereby facilitating deeper emotional exploration.”

MDMA “really does seem to make people want to interact more with other people,” says Harriet de Wit, PhD, a neuropharmacologist at the University of Chicago and one of the study’s authors. The results echo those of earlier research using psychedelics like LSD or psilocybin.

It’s important to note that any intervention involving MDMA or psychedelics would be a drug-assisted therapy — that is, used in conjunction with the appropriate therapy and in a therapeutic setting. MDMA-assisted therapy has already drawn popular and scientific attention, as it recently cleared clinical trials for treating posttraumatic stress disorder (PTSD) and may be nearing approval by the US Food and Drug Administration (FDA).

According to Friederike Holze, PhD, psychopharmacologist at the University of Basel, in Switzerland, “there could be a place” for MDMA and psychedelics in treating chronic loneliness, but only under professional supervision.

There would have to be clear guidelines too, says Joshua Woolley, MD, PhD, a psychiatrist at the University of California, San Francisco.

MDMA and psychedelics “induce this plastic state, a state where people can change. They feel open, they feel like things are possible,” Dr. Woolley says. Then, with therapy, “you can help them change.”

Pages

Recommended Reading

The cult of the suicide risk assessment
Federal Practitioner
Service dogs help veterans with PTSD lead better lives
Federal Practitioner
Federal Health Care Data Trends 2023
Federal Practitioner
Data Trends 2023: Depression
Federal Practitioner
Burnout in medical profession higher among women, younger clinicians
Federal Practitioner
Zuranolone: FAQs for clinicians and patients
Federal Practitioner
Esketamine bests quetiapine for severe depression in head-to-head trial
Federal Practitioner
Antidepressants ‘don’t blunt’ semaglutide and weight loss
Federal Practitioner
Specialized care may curb suicide risk in veterans with disabilities
Federal Practitioner
Ketamine no better for depression than placebo?
Federal Practitioner